一票制也不远了!127药企认定可视同生产企业药企

2017-01-13 半夏 赛柏蓝

安徽又放大招了! 在1月6日安徽食药监局公布了第一批认定可视同生产企业的52家药企后,1月10日,又进行第二批第一批认定可视同生产企业药企的公示,共有75家药企,公示时间1月10日~16日。综合两批认定的情况,共有127家药企被官方认定为可视同生产企业! ▍127家药企要火! 为什么说认定可视同生产企业药企的要火呢? 在国家正式公布《关于在公立医疗机构药品集中采购中推行“两票制

安徽又放大招了!

在1月6日安徽食药监局公布了第一批认定可视同生产企业的52家药企后,1月10日,又进行第二批第一批认定可视同生产企业药企的公示,共有75家药企,公示时间1月10日~16日。综合两批认定的情况,共有127家药企被官方认定为可视同生产企业!

▍127家药企要火!

为什么说认定可视同生产企业药企的要火呢?

在国家正式公布《关于在公立医疗机构药品集中采购中推行“两票制”的实施意见(试行)》,“两票制”正式落地后,业界更为关注的是接下来“两票制”的具体实施。

根据文件规定,两票制是指药品生产企业到流通企业开一次发票,流通企业到医疗机构开一次发票。药品生产企业或科工贸一体化的集团型企业设立的仅销售本企业(集团)药品的全资或控股商业公司(全国仅限一家商业公司)、境外药品国内总代理(全国仅限一家总代理)可视同生产企业。

对于众多药企而能言,此前最为关心的恐怕就是两票制如何界定。如今,按照国家文件规定,安徽所公布的药品生产企业设立的仅销售本公司(集团)产品的药品经营企业和进口药品国内总代理企业,都可视同生产企业,在生产企业和上述企业之间的药品流通不算作一票。

那么,未来这类药企很可能更成为药品流通企业合作的关键,因为从生产企业到这类企业是不算第一票的,却允许一定范围的加价。

同时,国家目前是推行“两票制”,鼓励“一票制”,从生产企业到这类企业不算第一票,那么这类企业若为医院配送药品的话,就是名义上的“一票制”了。未来,如果这类企业能承担起配送的职能,且规模不断壮大,那么,国家要实现“一票制”也是指日可待。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669273, encodeId=eb6b16692e363, content=<a href='/topic/show?id=63a7193815f' target=_blank style='color:#2F92EE;'>#一票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19381, encryptionId=63a7193815f, topicName=一票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65b126545306, createdName=tulenzi, createdTime=Tue Nov 14 02:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170476, encodeId=eb011e047635, content=无语!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/fa12b9d839f79e7b013736c17afada7e.jpg, createdBy=7c161987822, createdName=欧阳沁雪, createdTime=Sun Jan 15 09:49:31 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456051, encodeId=dbe21456051d4, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517716, encodeId=4eb3151e7168e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170271, encodeId=66111e0271e4, content=路过........, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEjPHcBWkEawnOHuvuXw3Lxjnzko8jRkakGyVZ27zRcmYACibkCom9Da1icAJBDFrbJelRNtMRic3H3/0, createdBy=152c1940043, createdName=Lke, createdTime=Sat Jan 14 10:42:18 CST 2017, time=2017-01-14, status=1, ipAttribution=)]
    2017-11-14 tulenzi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669273, encodeId=eb6b16692e363, content=<a href='/topic/show?id=63a7193815f' target=_blank style='color:#2F92EE;'>#一票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19381, encryptionId=63a7193815f, topicName=一票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65b126545306, createdName=tulenzi, createdTime=Tue Nov 14 02:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170476, encodeId=eb011e047635, content=无语!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/fa12b9d839f79e7b013736c17afada7e.jpg, createdBy=7c161987822, createdName=欧阳沁雪, createdTime=Sun Jan 15 09:49:31 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456051, encodeId=dbe21456051d4, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517716, encodeId=4eb3151e7168e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170271, encodeId=66111e0271e4, content=路过........, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEjPHcBWkEawnOHuvuXw3Lxjnzko8jRkakGyVZ27zRcmYACibkCom9Da1icAJBDFrbJelRNtMRic3H3/0, createdBy=152c1940043, createdName=Lke, createdTime=Sat Jan 14 10:42:18 CST 2017, time=2017-01-14, status=1, ipAttribution=)]
    2017-01-15 欧阳沁雪

    无语!!!!!!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1669273, encodeId=eb6b16692e363, content=<a href='/topic/show?id=63a7193815f' target=_blank style='color:#2F92EE;'>#一票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19381, encryptionId=63a7193815f, topicName=一票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65b126545306, createdName=tulenzi, createdTime=Tue Nov 14 02:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170476, encodeId=eb011e047635, content=无语!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/fa12b9d839f79e7b013736c17afada7e.jpg, createdBy=7c161987822, createdName=欧阳沁雪, createdTime=Sun Jan 15 09:49:31 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456051, encodeId=dbe21456051d4, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517716, encodeId=4eb3151e7168e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170271, encodeId=66111e0271e4, content=路过........, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEjPHcBWkEawnOHuvuXw3Lxjnzko8jRkakGyVZ27zRcmYACibkCom9Da1icAJBDFrbJelRNtMRic3H3/0, createdBy=152c1940043, createdName=Lke, createdTime=Sat Jan 14 10:42:18 CST 2017, time=2017-01-14, status=1, ipAttribution=)]
    2017-01-15 hyf030
  4. [GetPortalCommentsPageByObjectIdResponse(id=1669273, encodeId=eb6b16692e363, content=<a href='/topic/show?id=63a7193815f' target=_blank style='color:#2F92EE;'>#一票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19381, encryptionId=63a7193815f, topicName=一票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65b126545306, createdName=tulenzi, createdTime=Tue Nov 14 02:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170476, encodeId=eb011e047635, content=无语!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/fa12b9d839f79e7b013736c17afada7e.jpg, createdBy=7c161987822, createdName=欧阳沁雪, createdTime=Sun Jan 15 09:49:31 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456051, encodeId=dbe21456051d4, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517716, encodeId=4eb3151e7168e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170271, encodeId=66111e0271e4, content=路过........, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEjPHcBWkEawnOHuvuXw3Lxjnzko8jRkakGyVZ27zRcmYACibkCom9Da1icAJBDFrbJelRNtMRic3H3/0, createdBy=152c1940043, createdName=Lke, createdTime=Sat Jan 14 10:42:18 CST 2017, time=2017-01-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1669273, encodeId=eb6b16692e363, content=<a href='/topic/show?id=63a7193815f' target=_blank style='color:#2F92EE;'>#一票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19381, encryptionId=63a7193815f, topicName=一票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65b126545306, createdName=tulenzi, createdTime=Tue Nov 14 02:31:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170476, encodeId=eb011e047635, content=无语!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/fa12b9d839f79e7b013736c17afada7e.jpg, createdBy=7c161987822, createdName=欧阳沁雪, createdTime=Sun Jan 15 09:49:31 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456051, encodeId=dbe21456051d4, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517716, encodeId=4eb3151e7168e, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sun Jan 15 00:31:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=170271, encodeId=66111e0271e4, content=路过........, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLEjPHcBWkEawnOHuvuXw3Lxjnzko8jRkakGyVZ27zRcmYACibkCom9Da1icAJBDFrbJelRNtMRic3H3/0, createdBy=152c1940043, createdName=Lke, createdTime=Sat Jan 14 10:42:18 CST 2017, time=2017-01-14, status=1, ipAttribution=)]
    2017-01-14 Lke

    路过........

    0

相关资讯

两票制还没完,一票制又来了,到底是个什么鬼?

这两天真相帝周围的朋友都在传一篇文章《浙江一票制或使大批亿元经销商瞬间休克,谁将是赢家》。真相帝点开链接进去,却发现语焉不详,啥干货也么有。 经过真相帝仔细研究,终于搞清楚一票制原来是这么个鬼!首先,啥是一票制?一票制就是药厂直接开票到医院,不经过批发商,可以通过配送商配送,但是配送商的费用由药厂直接支付给配送商。 通俗点说:原来医院是风流大官人西门庆,药厂是风流女子潘金莲,大

一票制真的来了!医院已接到通知

“一票制”目前对于全国来说还算是较新鲜的字眼,但是,对于福建省来说,这已是众多药企的心头之痛。 近日,有业内人士向赛柏蓝反映,一份福建省卫计委医院管理局戳红章,名为《关于省属公立医院基础输液确标的通知》的内部文件,直接下发到医院,文件明确要求医院根据第一、二批基础输液限价挂网结果进行选择采购,医院和药品生产企业直接结算,严格执行“一票制”。 面对这份严格执行“一票制”的文件,许

“两票制”or“一票制” 药企出路在何方?

4月6日,由国家总理李克强主持的国务院常务会议提出了,从生产到流通和从流通到医疗机构各开一次发票的“两票制”,从此“两票制”成为医药人的关注点。两票制实施以来对整个医药行业影响重大,已经对全国5065家药品生产企业、近2万亿药物的销售体系产生重构影响。 “两票制”政策的主旨是砍掉药品流通中间环节,以期降低药品的销售价格,从而降低医保费用。 依据相关部

央视曝光药品回扣明细 发改委要推一票制

12月24日,央视新闻调查再度让药品回扣这一业内“潜规则”曝光。央视报道出来后,上海和湖南卫计委迅速展开调查,目前湖南已有一名医生被停职。 上一次央视报道药品回扣时间为2011年,其主题为:央视曝光药品惊人回扣,出厂价6毛医院卖12元。   2011年央视的报道虽然也谈及药品回扣,但是最终拷问的是为何出厂价和医院销售价格之间有如此大差异,当时报道的结论是,这一事件的根源在于药品